30.47

0.59% -0.18

After Hours: 30.47

Indivior Pharmaceuticals Inc (INDV)

Overview News Price History Discussions Forecast

Indivior Pharmaceuticals Inc stock is traded at $30.47, with a volume of 2.15M. It is down -0.59% in the last 24 hours and down -4.72% over the past month. Indivior Pharmaceuticals Inc is a specialty pharmaceutical company singularly focused on delivering evidence-based treatment and advancing understanding of opioid use disorder (OUD) as a chronic but treatable brain disease. The company derives revenues from customers through the development, manufacture and sale of buprenorphine-based prescription drugs for treatment of opioid dependence and related disorders. The company's products include: Sublocade (buprenorphine extended-release monthly injection), and Suboxone (buprenorphine and naloxone sublingual film).

Previous Close:

$30.65

Open:

$29.99

24h Volume:

2.15M

Relative Volume:

0.89

Market Cap:

$3.71B

Revenue:

$1.24B

Net Income/Loss:

$209.00M

P/E Ratio:

18.35

EPS:

1.6605

Net Cash Flow:

$-94.86M

1W Performance:

+1.74%

1M Performance:

-4.72%

6M Performance:

+31.00%

1Y Performance:

+220.06%

1-Day Range:

$29.65

$30.57

1-Week Range:

$28.66

$31.25

52-Week Range:

$8.64

$38.00

Indivior Pharmaceuticals Inc Stock (INDV) Company Profile

Name

Indivior Pharmaceuticals Inc

Sector

Healthcare (1118)

Industry

Drug Manufacturers - Specialty & Generic (84)

Phone

804-379-1090

Address

10710 MIDLOTHIAN TURNPIKE, NORTH CHESTERFIELD

Employee

838

Twitter

Next Earnings Date

2026-04-23

Latest SEC Filings

INDV's Discussions on Twitter

Compare INDV vs TAK, ZTS, HLN, TEVA, UTHR

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
INDV Indivior Pharmaceuticals Inc	30.47	3.71B	1.24B	209.00M	-94.86M	1.6605
TAK Takeda Pharmaceutical Co Adr	18.74	59.20B	29.85B	776.90M	4.35B	0.2408
ZTS Zoetis Inc	117.94	49.79B	9.47B	2.67B	2.28B	6.0218
HLN Haleon Plc Adr	9.93	44.27B	14.54B	2.22B	2.58B	0.4871
TEVA Teva Pharmaceutical Industries Ltd Adr	30.08	35.03B	17.41B	1.43B	1.00B	1.2182
UTHR United Therapeutics Corp	564.81	24.75B	3.18B	1.33B	1.04B	27.90

Indivior Pharmaceuticals Inc Stock (INDV) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Aug-06-25	Initiated	H.C. Wainwright	Buy
Jul-22-25	Resumed	Jefferies	Buy
Jan-28-25	Initiated	Rodman & Renshaw	Buy
Jul-23-24	Initiated	Piper Sandler	Overweight
Apr-03-24	Initiated	Craig Hallum	Buy
Jul-13-23	Initiated	Northland Capital	Outperform

View All

Indivior Pharmaceuticals Inc Stock (INDV) Latest News

05:18 AM

Indivior, Liquidia, Crinetics top Quant pharma list as Merck scoops up Terns for $6.7B - MSN

05:18 AM

05:04 AM

JPMorgan Chase & Co. Has $5.01 Million Holdings in Indivior PLC $INDV - MarketBeat

05:04 AM

04:43 AM

Did Potential Jail Staffing Efficiencies From SUBLOCADE® Just Shift Indivior Pharmaceuticals' (INDV) Investment Narrative? - Sahm

04:43 AM

Apr 02, 2026

Down 12.9% in 4 Weeks, Here's Why You Should You Buy the Dip in Indivior Pharmaceuticals Inc. (INDV) - MSN

Apr 02, 2026

Apr 01, 2026

What Indivior Pharmaceuticals (INDV)'s Prison Cost Model Findings Mean For Shareholders - Yahoo Finance

Apr 01, 2026

AGIO Rises on Mitapivat Progress Toward Accelerated Approval in SCD - The Globe and Mail

Apr 01, 2026

Mar 31, 2026

Indivior Pharmaceuticals, Inc - Reuters

Mar 31, 2026

Ultragenyx Pharmaceutical Announces FDA Acceptance of UX016 IND - TradingView

Mar 31, 2026

New Cost Impact Model Highlights Potential Benefits of Monthly Injectable Buprenorphine - National Today

Mar 31, 2026

New Cost Model Shows Monthly Injectable Buprenorphine Can Reduce Staffing Burdens in Prisons - National Today

Mar 31, 2026

New Cost Impact Model Highlights Potential for Monthly Injectable Buprenorphine to Reduce Staffing Burdens in Correctional Facilities - The Manila Times

Mar 31, 2026

Monthly opioid addiction shot may cut jail staffing, model estimates - Stock Titan

Mar 31, 2026

Zacks.com spotlights Indivior, Ciena, and Ultra Clean as notable mentions - Bitget

Mar 31, 2026

Zacks.com featured highlights include Indivior, Ciena and Ultra Clean - Yahoo Finance

Mar 31, 2026

FOCUS-Drugmakers delay some European launches with a wary eye on Trump's pricing policies - Sahm

Mar 31, 2026

Indivior PLC (NASDAQ:INDV) Short Interest Up 21.7% in March - MarketBeat

Mar 31, 2026

Mar 30, 2026

Indivior: Still Attractive After FY25 Earnings Beat (NASDAQ:INDV) - Seeking Alpha

Mar 30, 2026

Is It Time To Reassess Indivior Pharmaceuticals (INDV) After Its 200% One Year Surge? - simplywall.st

Mar 30, 2026

Hennion & Walsh Asset Management Inc. Purchases 96,177 Shares of Indivior PLC $INDV - MarketBeat

Mar 30, 2026

Mar 29, 2026

If You Invested $1,000 in Indivior Pharmaceuticals Inc. (INDV) - Stock Titan

Mar 29, 2026

SG Americas Securities LLC Buys 363,829 Shares of Indivior PLC $INDV - MarketBeat

Mar 29, 2026

Indivior PLC (NASDAQ:INDV) Given Average Recommendation of "Buy" by Analysts - MarketBeat

Mar 29, 2026

Mar 28, 2026

Levi & Korsinsky Reminds Indivior Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of October 1, 2024INDV - MarketScreener

Mar 28, 2026

Mar 27, 2026

Indivior (INDV) posts 2025 growth, SUBLOCADE gains and $400M buyback in 2026 proxy - Stock Titan

Mar 27, 2026

Suboxone Market Size Forecasts 2026-2033: Analyzing Industry - openPR.com

Mar 27, 2026

Mar 25, 2026

Indivior PLC Stock Faces Uncertainty Amid U.S. Domicile Shift and OUD Market Focus - AD HOC NEWS

Mar 25, 2026